Matthew Klein, M.D., M.S., FACS

Title: Chief Operating Officer

Organization: PTC Therapeutics

Bio: Matthew B. Klein, M.D., M.S., FACS, is chief operating officer at PTC. Prior to joining PTC, Dr. Klein was chief executive officer of BioElectron Technology Corporation, a biotechnology company focused on the development of redox-active small molecules for mitochondrial disease and related disorders of oxidative stress. Before joining BioElectron, Dr. Klein was the Auth-Washington Research Foundation chair of restorative burn surgery at the University of Washington. Dr. Klein completed his bachelor’s degree in history and chemistry at the University of Pennsylvania where he graduated summa cum laude and Phi Beta Kappa. Dr. Klein earned his medical degree with honors from Yale University.

Beyond Dystrophin Panel

This conference session provides insight and updates from companies whose therapies target critical aspects of the Duchenne disease process that occur alongside reductions in dystrophin.

Abby Bronson

Vice President, Patient Advocacy & External Innovation

Edgewise Therapeutics

See more from same speaker

Mindy Cameron

Patient Advocacy Lead

Santhera Pharmaceuticals

See more from same speaker

Matthew Klein, M.D., M.S., FACS

Chief Operating Officer

PTC Therapeutics

See more from same speaker

Daniel Paulson, MD

Vice President of Clinical Development

Capricor Therapeutics

See more from same speaker

Han Phan, MD

Director

Rare Disease Research, LLC

See more from same speaker

Video
Share this:
Beginning the Journey - diagnosed 0-3 yearsGrowth and Transformation - diagnosed 3-6 yearsSpreading Wisdom - diagnosed 6+ years

Exon Skipping and Read Through Agents Panel

A brief introduction on the rationale behind mechanisms of endogenous dystrophin restoration, like exon skipping and read through agent therapies, followed by critical information and updates from the companies in this space. Moderated discussion included.

Barry Byrne, MD, PhD

Professor and Associate Chair

University of Florida, Department of Pediatrics

See more from same speaker

Jay Chauhan, PharmD

Medical Science Liaison

NS Pharma

See more from same speaker

Brett Crawford, PhD

Executive Director and Head of the Musculoskeletal Therapeutic Area

BioMarin Pharmaceutical Inc.

See more from same speaker

Ash Dugar, PhD

Senior Vice President, Medical Affairs

Dyne Therapeutics

See more from same speaker

Xiao Shelley Hu, PhD, MS

VP

Wave Life Sciences

See more from same speaker

Matthew Klein, M.D., M.S., FACS

Chief Operating Officer

PTC Therapeutics

See more from same speaker

Nerissa Kreher, MD, MBA

Chief Medical Officer

Entrada Therapeutics

See more from same speaker

James McArthur, PhD

President and Chief Executive Officer

PepGen

See more from same speaker

Mark Stahl, MD, PhD

Senior Medical Director, Clinical Development

Avidity Biosciences

See more from same speaker

Deanna Tucker, PharmD

Senior Medical Science Liaison

Sarepta Therapeutics

See more from same speaker

Video
Share this:
Beginning the Journey - diagnosed 0-3 yearsGrowth and Transformation - diagnosed 3-6 years

Más allá de la distrofina

Esta sesión de la conferencia brinda información sobre las terapias emergentes más allá de la restauración de la distrofina, así como actualizaciones/anuncios de las empresas en este espacio.

Han Phan, MD

Director

Rare Disease Research, LLC

See more from same speaker

Mindy Cameron

Patient Advocacy Lead

Santhera Pharmaceuticals

See more from same speaker

Matthew Klein, M.D., M.S., FACS

Chief Operating Officer

PTC Therapeutics

See more from same speaker

Abby Bronson

Vice President, Patient Advocacy & External Innovation

Edgewise Therapeutics

See more from same speaker

Daniel Paulson, MD

Vice President of Clinical Development

Capricor Therapeutics

See more from same speaker

Video
Share this:
Spreading Wisdom - diagnosed 6+ yearsGrowth and Transformation - diagnosed 3-6 years